Researchers Mull Impact of Geron's Sudden Exit From Field

See allHide authors and affiliations

Science  25 Nov 2011:
Vol. 334, Issue 6059, pp. 1043
DOI: 10.1126/science.334.6059.1043

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


The decision last week by the biotech company Geron to cancel the first-ever clinical trial using human embryonic stem cells (hESCs) and sell off its stem cell programs has shaken the biomedical research community. Some worry that Geron's announcement, which the company attributes to financial concerns, will dampen enthusiasm from other companies and the public for hESC research. But others see the half-completed trial as smoothing the way for future human studies.

  • * With reporting by Gretchen Vogel.